- Cetuximab (CAS 205923-56-4) is a high-purity pharmaceutical API classified as an EGFR Inhibitor, featuring a chimeric (mouse-human) IgG1 monoclonal antibody structure with high specificity for epidermal growth factor receptor (EGFR). It binds selectively to the extracellular domain of EGFR, blocking ligand binding and downstream signaling pathways that drive cancer cell proliferation, migration, and angiogenesis. This premium API exhibits strong target affinity and stable bioactivity, ensuring consistent performance in intravenous injectable formulations.
- It caters to the core needs of oncology drug manufacturers, biotech research institutions, and clinical trial suppliers. Widely applied in developing treatments for metastatic colorectal cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer, it aligns with the demand for targeted anti-EGFR therapies. Produced under strict GMP-compliant biomanufacturing processes, each batch undergoes rigorous purity and potency testing to meet global biopharmaceutical standards. For businesses prioritizing precise, mechanism-driven anticancer solutions, this Cetuximab API serves as a critical raw material for advancing oncology therapy research and clinical applications.
Cetuximab (CAS 205923-56-4) – Anti-EGFR Chimeric Monoclonal Antibody Anticancer API
$24,000.00
Cetuximab – Anti-EGFR Chimeric Monoclonal Antibody Anticancer is an active pharmaceutical ingredient (API) primarily used in the formulation of pharmaceutical products for the treatment, prevention, or diagnosis of various diseases and medical conditions.
Be the first to review “Cetuximab (CAS 205923-56-4) – Anti-EGFR Chimeric Monoclonal Antibody Anticancer API”
Reviews
There are no reviews yet.